Pharma BD Deal Intelligence
Hospira, Inc. / Javelin Pharmaceuticals, Inc.
2010 · Acquisition/Merger · $145M · Complete
Announcement Sentiment
71
Positive
Hospira to acquire Javelin Pharmaceuticals for ~$145M, adding Dyloject IV pain product. Tender offer completed July 1, 2010.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Assessment window: 15yr post-close.
Key facts
- Announced Apr 29, 2010
- Closed Jul 01, 2010
- Deal value $145M
- Deal type Acquisition/Merger
- Therapeutic area Post-operative pain management
- Indications Post-operative pain management
- Key assets Dyloject (diclofenac IV)
- Mechanism NSAID injectable
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals